Last reviewed · How we verify

Tetravalent influenza virus lysis vaccine

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Phase 3 active Biologic

Tetravalent influenza virus lysis vaccine is a Inactivated influenza vaccine Biologic drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. It is currently in Phase 3 development for Prevention of seasonal influenza (tetravalent strains).

A tetravalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus through viral antigen presentation.

A tetravalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus through viral antigen presentation. Used for Prevention of seasonal influenza (tetravalent strains).

At a glance

Generic nameTetravalent influenza virus lysis vaccine
SponsorAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Drug classInactivated influenza vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

This vaccine contains inactivated (killed) influenza virus particles representing four circulating strains (two influenza A subtypes and two influenza B lineages). Upon administration, the viral antigens trigger both humoral (antibody) and cellular immune responses, priming the immune system to recognize and neutralize these influenza strains if encountered naturally. The vaccine aims to reduce infection rates, severity of illness, and complications from seasonal influenza.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tetravalent influenza virus lysis vaccine

What is Tetravalent influenza virus lysis vaccine?

Tetravalent influenza virus lysis vaccine is a Inactivated influenza vaccine drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., indicated for Prevention of seasonal influenza (tetravalent strains).

How does Tetravalent influenza virus lysis vaccine work?

A tetravalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus through viral antigen presentation.

What is Tetravalent influenza virus lysis vaccine used for?

Tetravalent influenza virus lysis vaccine is indicated for Prevention of seasonal influenza (tetravalent strains).

Who makes Tetravalent influenza virus lysis vaccine?

Tetravalent influenza virus lysis vaccine is developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (see full Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. pipeline at /company/anhui-zhifei-longcom-biologic-pharmacy-co-ltd).

What drug class is Tetravalent influenza virus lysis vaccine in?

Tetravalent influenza virus lysis vaccine belongs to the Inactivated influenza vaccine class. See all Inactivated influenza vaccine drugs at /class/inactivated-influenza-vaccine.

What development phase is Tetravalent influenza virus lysis vaccine in?

Tetravalent influenza virus lysis vaccine is in Phase 3.

What are the side effects of Tetravalent influenza virus lysis vaccine?

Common side effects of Tetravalent influenza virus lysis vaccine include Injection site pain or erythema, Myalgia, Headache, Fatigue, Low-grade fever.

Related